Keyword: Novartis Sun Pharma
Sun Pharmaceutical's buyout of troubled Ranbaxy Laboratories this year came with the chore of facing the issues that led the FDA to ban four Ranbaxy plants in India. But now Sun finds itself cleaning up a mess from Ranbaxy's U.S. manufacturing operation, Ohm Laboratories, which has led it to recall more than 1 million boxes of a product it produced for private-label customers.
Two years ago, Sun Pharma was before the U.S. Supreme Court defending a label for one of its generic drugs against claims that it didn't adequately warn against risks. Now the labels on some of its drugs are creating another kind of problem, leading to a recall of more than 216,000 bottles of drugs.